Medical XpressPulling the plug on the first gene therapy drugMedical XpressMy book about gene therapy was published in 2012, the year that the European Medicines Agency (EMA) approved Glybera. I was certain that the first approvals in the US would come… Continue reading
|
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
P&T Community “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … |
|
Ziopharm Oncology (ZIOP) Says FDA Accepts IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
StreetInsider.com “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … |
Medical Xpress |
First patient receives experimental immunotherapy for cancer
Medical Xpress “In recent years, immunotherapy has shown great promise in treating certain kinds of cancer, but we’re still at the early stages of understanding and optimizing this approach.” said Dr. Garth Nicholas, medical oncologist and trial leader at The Ottawa … |
|
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
Yahoo Finance “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … |
Chaffey Breeze |
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
Yahoo Finance “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … Ziopharm Oncology: Key To The CAR–T MintSeeking Alpha |
|
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR–T Cell Therapy Targeting Relapsed …
GlobeNewswire (press release) “In vivo preclinical animal studies have demonstrated that these CAR–T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls, and I look forward to evaluating … |